$256.01 Million in Sales Expected for Alkermes Plc (ALKS) This Quarter
Wall Street analysts expect Alkermes Plc (NASDAQ:ALKS) to post $256.01 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Alkermes’ earnings, with the lowest sales estimate coming in at $254.10 million and the highest estimate coming in at $258.10 million. Alkermes reported sales of $275.37 million in the same quarter last year, which would indicate a negative year over year growth rate of 7%. The firm is expected to report its next earnings results on Wednesday, February 13th.
According to Zacks, analysts expect that Alkermes will report full year sales of $1.04 billion for the current year, with estimates ranging from $1.03 billion to $1.04 billion. For the next fiscal year, analysts forecast that the firm will post sales of $1.11 billion, with estimates ranging from $958.60 million to $1.22 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Alkermes.
Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Tuesday, October 23rd. The company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.15. Alkermes had a negative net margin of 13.23% and a negative return on equity of 0.12%. The business had revenue of $248.72 million during the quarter, compared to the consensus estimate of $236.70 million. During the same period in the previous year, the firm posted $0.03 earnings per share. The business’s revenue for the quarter was up 14.4% compared to the same quarter last year.
Shares of NASDAQ:ALKS traded down $0.29 on Tuesday, hitting $41.38. 804,564 shares of the company were exchanged, compared to its average volume of 847,949. Alkermes has a 1-year low of $37.01 and a 1-year high of $71.22. The company has a current ratio of 2.85, a quick ratio of 2.62 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $6.43 billion, a P/E ratio of -111.84 and a beta of 1.72.
In other Alkermes news, Director Paul J. Mitchell sold 1,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $44.58, for a total value of $44,580.00. Following the completion of the transaction, the director now owns 8,000 shares in the company, valued at $356,640. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 3,000 shares of company stock valued at $130,680. Insiders own 5.34% of the company’s stock.
Institutional investors have recently modified their holdings of the business. First Trust Advisors LP increased its stake in shares of Alkermes by 67.1% during the third quarter. First Trust Advisors LP now owns 2,196,134 shares of the company’s stock worth $93,204,000 after purchasing an additional 881,946 shares in the last quarter. Janus Henderson Group PLC grew its stake in Alkermes by 0.9% during the 2nd quarter. Janus Henderson Group PLC now owns 2,037,737 shares of the company’s stock valued at $83,873,000 after acquiring an additional 18,781 shares in the last quarter. Northern Trust Corp grew its stake in Alkermes by 3.0% during the 2nd quarter. Northern Trust Corp now owns 876,000 shares of the company’s stock valued at $36,056,000 after acquiring an additional 25,526 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Alkermes by 5.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 567,198 shares of the company’s stock valued at $23,346,000 after acquiring an additional 30,410 shares in the last quarter. Finally, First Manhattan Co. boosted its holdings in Alkermes by 55,499.4% in the 3rd quarter. First Manhattan Co. now owns 555,994 shares of the company’s stock valued at $23,596,000 after purchasing an additional 554,994 shares during the last quarter.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.
Recommended Story: How can you know how many shares are floating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.